Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 22;13(2):170. doi: 10.1038/s41419-022-04614-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A Flowchart illustrating the different steps in the analysis of significantly dysregulated RBPs in UCB patients. B, C Heatmap showing the mRNA expression levels of significantly dysregulated RBPs in the SYSUCC (B) and TCGA (C) cohorts. D Distribution of FXR1 mRNA expression in tumors compared with matched normal samples from the SYSUCC (left) and TCGA (right) cohorts. E Survival analysis indicates the correlation between high FXR1 expression levels and poor OS rates in TCGA UCB patients. HR hazard ratio, CI confidence interval. F Western blot showing the upregulated expression of FXR1 in eight paired UCB tissues. G Representative images of IHC staining for FXR1 in nonneoplastic bladder tissue, low-grade UCB, and high-grade UCB. H, I Survival analysis showing that high expression of FXR1 predicts poor DFS and OS rates in SYSUCC UCB patients.